AOCNP Immunotherapy and Targeted Therapy 5

Question 1

A patient on ipilimumab develops grade 2 immune-mediated colitis with 4–6 loose stools per day. Which intervention is most appropriate?

Accepted Answer

Hold ipilimumab and initiate oral prednisone 0.5–1 mg/kg/day

Answer

Grade 2 immune-mediated colitis requires holding the offending agent and starting oral corticosteroids at 0.5–1 mg/kg/day.

Question 2

Which targeted therapy requires RET fusion testing prior to use in NSCLC?

Accepted Answer

Selpercatinib

Answer

Selpercatinib is a selective RET inhibitor indicated for NSCLC with RET fusions, which must be confirmed by molecular testing.

Question 3

A patient receiving atezolizumab develops new-onset polyuria, polydipsia, and hyperglycemia. Which immune-related endocrinopathy should be suspected?

Accepted Answer

Type 1 diabetes mellitus

Answer

Checkpoint inhibitors can trigger autoimmune type 1 diabetes, presenting with new hyperglycemia and symptoms of insulin deficiency.

Question 4

Trastuzumab emtansine (T-DM1) is classified as which type of targeted agent?

Accepted Answer

Antibody-drug conjugate

Answer

T-DM1 is an antibody-drug conjugate that links trastuzumab to the cytotoxic agent DM1, delivering chemotherapy selectively to HER2-overexpressing cells.

Question 5

Which statement best describes the role of tumor mutational burden (TMB) in immunotherapy?

Accepted Answer

High TMB is associated with more neoantigens and potentially greater response to checkpoint inhibitors

Answer

Tumors with high TMB produce more neoantigens, which can be recognized by the immune system, potentially enhancing response to checkpoint inhibitors.

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP Immunotherapy and Targeted Therapy 5